Krystexxa pegloticase regulatory update

FDA's Arthritis Advisory Committee will meet on June 16 to discuss a BLA from Savient for Krystexxa pegloticase for treatment failure gout. In February, FDA extended the review by 3 months to Aug. 1 f...